Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
Xianhuo Wang(Shanghai Jiao Tong University), Huilai Zhang(Shanxi Medical University)
Cited by 4
Related Papers
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
|The Lancet Oncology|2023|55
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
|Journal of Hematology & Oncology|2020|50
ADAR1-mediated RNA editing promotes B cell lymphomagenesis
|iScience|2023|24
Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients
|Journal of Cancer|2020|22